Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in Advanced Adrenocortical Carcinoma
NCT03257891Phase 2Unknown
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jan 2018
- Primary completion
- Jan 2021
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel in adrenocortical carcinoma (ACC), sponsored by ASST Spedali Civili di Brescia. Status: unknown.
02
Drugs
cabazitaxel
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT03257891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257891.